VERAXA Biotech (NASDAQ: VRXA) is showcasing its proprietary BiTAC-ADC and BiTAC-TCE technology platforms at the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity. These findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications.
Management plans to discuss partnering opportunities for both technologies at the convention, which brings together leaders from the biotech and pharmaceutical industries. The BiTAC platforms represent a significant advancement in antibody-based therapeutics, combining bispecific T cell engagers and bispecific ADCs to target cancer cells more effectively while reducing harm to healthy tissue. The new data underscore the platforms' ability to activate therapeutic agents specifically within the tumor microenvironment, a key challenge in oncology.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, guided by rigorous quality-by-design principles. Their pipeline includes ADCs and proprietary BiTAC formats moving into clinical development and beyond.
For more information on the press release, visit https://ibn.fm/r8zEz. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties, including those set forth in the company's filings with the SEC. These statements are based on information available as of the date hereof, and the company undertakes no duty to update them unless required by law.
